MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
about
miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway.Combine and conquer: challenges for targeted therapy combinations in early phase trials.MTOR inhibitor-based combination therapies for pancreatic cancer.Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
P2860
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@en
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@nl
type
label
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@en
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@nl
prefLabel
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@en
MEK plus PI3K/mTORC1/2 Therape ...... l Models of Colorectal Cancer.
@nl
P2093
P2860
P50
P1476
MEK plus PI3K/mTORC1/2 Therape ...... al Models of Colorectal Cancer
@en
P2093
Andrea Bertotti
Celina García-García
Claudia Aura
Guillem Argilés
Irene Chicote
José Baselga
Judit Grueso
Judit Matito
Katti Jessen
Livio Trusolino
P2860
P304
P356
10.1158/1078-0432.CCR-14-3091
P407
P50
P577
2015-08-13T00:00:00Z